ADA-friendly PDF: Consensus Statement Regarding the Use of Trastuzumab Deruxtecan (T-DXd) in Patients with Metastatic, HER2-low Breast Cancer

Treatment Guidelines: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer

Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC)  meetings held on October 15 and November 5, 2021, was to discuss recommendations for the use of abemaciclib in patients with early-stage, high-risk, HR+ breast cancer.